Abstract: Oral formulations comprising one or more proteasome inhibitors for use as a treatment of coronavirus infection in a subject. Also disclosed are the use of such for the treatment or prevention of SARS-CoV-2 infection in humans.

Abstract: The present invention relates in part to a method of fabricating multimetallic nanoparticles, the method comprising the steps of providing a substrate; activating the substrate surface; adsorbing a cationic transition metal complex onto the substrate surface to form a substrate-supported cationic transition metal complex; adsorbing an anionic transition metal complex onto the substrate-supported cationic transition metal complex to form a substrate-supported multimetallic complex salt; and reducing the substrate-supported multimetallic complex salt to provide a plurality of multimetallic nanoparticles. The invention also relates in part to a composition of multimetallic nanoparticles comprising at least two metals Ma and Mb; wherein the ratio of Ma to Mb is between about 2:1 and about 1:2.

Abstract: This invention comprises compositions and methods to determine the prognosis of necrotizing enterocolitis.

Abstract: The present disclosure provides for sampling instruments and methods of collecting sample particles. The sampling instrument can include a high-pressure pulsed valve coupled to a gas flow system to displace a sample from a surface. Also included can be a voltage supply coupled to a voltage switch, a suction device, a sample collector, and a collection filter. To collect a sample, extractive particles can be deposited onto a sample present on a substrate. At least a portion of the sample becomes coupled to a portion of the extractive particles to form sample particles. High-pressure gas can be discharged at the sample, thereby aerosolizing a portion of the sample particles to disperse aerosolized sample particles. A portion of the aerosolized sample particles can be collected onto a collection filter to form a collected sample.

Abstract: A method of preventing or reducing the occurrence and/or development of a hernia within a subject at risk of developing a hernia includes implanting a graft material in contact with an opening in an abdominal wall. The graft material promotes healing of the abdominal wall and includes placental or placental derived tissue.

Abstract: The invention relates to a Quadruple Gene Deleted Mutant Bovine Herpesvirus Type 1 (BHV-1 QMV) engineered to express protective antigens derived from viruses associated with infection in livestock. The recombinant vector includes a deletion of a cytoplasmic tail of envelope glycoprotein gE (gE-CT), a truncation of glycoprotein gG, a deletion of envelope protein UL49.5 amino acid residues 30-32, and a deletion of UL49.5 cytoplasmic tail amino acid residues 80-96. The truncation of glycoprotein gG comprises a deletion of amino-terminal amino acid residues 1-67. The recombinant vector can include at least two heterologous antigens inserted therein.

Abstract: According to some embodiments of the invention, a near-infrared fluorescence endoscopic dental imaging system includes an endoscope forming a plurality of lumens therein; a spectrometer optically coupled to a first lumen of the endoscope; a near-infrared camera optically coupled to a second lumen of the endoscope; a data processor in communication with the spectrometer and the near-infrared camera; and a display system in communication with the data processor. The near-infrared camera is configured to capture a near-infrared two-dimensional dental image of a specimen and transmit the near-infrared two-dimensional dental image to the data processor. The spectrometer is configured to capture fluorescent light from the specimen and provide a spectroscopic signal to the data processor. The display system is configured to communicate with the data processor to receive the near-infrared two-dimensional dental image and the spectroscopic signal and to display a two-dimensional dental image of the specimen.

Abstract: The absorbance or emission wavelength of composite materials comprising a transition metal doped shell disposed over a rare earth doped core and a functionalizable group on the surface of the transition metal doped shell can change upon subjection to a carboxylic acid. This method of changing the absorbance or emission wavelength of a composite material can be used to identify counterfeit currency using an ink comprising a composite material.

Abstract: Therapeutics and methods of diagnosing non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) in a patient comprising obtaining a sample from the patient, determining a level of a signaling lymphocytic activation molecule 1 (SLAMF1) in the sample from the patient, and diagnosing the patient with NAFLD when the level of the SLAMF1 is at least an elevated threshold level for the SLAMF1. Therapeutics and methods of treating non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) in a patient in need of treatment comprising administering a pharmaceutically effective dose of a therapeutic, wherein the therapeutic includes a signaling lymphocytic activation molecule 1 (SLAMF1) antagonist.

Abstract: Disclosed are highly active cationic cobalt phosphine complexes, both mono- and bimetallic, that can catalyze hydroformylation reactions. The disclosed catalysts can be utilized in methods that provide reaction processes that are hundreds of times faster than high pressure HCo(CO)4 or phosphine-modified HCo(CO)3(PR3) catalysts and operate at considerably lower pressures and temperatures. Also disclosed are methods of hydroformylation using the described transition metal complexes. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

Abstract: A method of treating or preventing methamphetamine related endothelial dysfunction in a patient comprising administering to the patient an effective dose of a pharmacologic composition; the composition comprising a therapeutic, the therapeutic including a hydrogen sulfide (H2S) donor, or a salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analogs thereof. The H2S donor may be one of sodium sulfide, diallyl trisulfide, diallyl disulfide, acillin, sugammadex, sulfanilamide, disulfram, sulfonamide, sulfinates, sulfoxides, persulfides, polysulfides, and sulfones. The H2S donor may be sugammadex. The H2S donor may be administered in a dosage of between 0.5 mg/kg and 10.0 mg/kg.

Abstract: The present invention is based, in part, on our discovery that certain types of therapeutic agents can be used in combination to treat a variety of neuropsychiatric and related disorders, including addiction (e.g., to a substance or to an activity) as well as to alleviate some of the symptoms experienced during menopause or associated with the menstrual cycle. Regardless of the precise formulation, the compositions of the invention can include at least one active ingredient that targets the hypothalamopituitary-adrenal (HPA) axis and at least one active ingredient that targets the prefrontal cortex. Either or both of these types of agents can be combined with an agent that inhibits activity in the sympathetic nervous system. Thus, the compositions or combination pharmacotherapies can also include an agent that inhibits a beta-adrenergic receptor or that otherwise acts as an anti-hypertensive or anxiolytic agent.

Abstract: The present invention provides rolled scaffold devices and cell culture systems that can provide a large surface-area-to-volume ratio for expanded cell culture. The rolled scaffolds minimize shear stress on cultured cells and support sufficient and uniform mass transfer rates of gases and nutrients. The rolled scaffolds can be connected to a media source via holders to support large-scale expansion and maintenance of cell cultures.

Abstract: A method of treating or preventing methamphetamine related endothelial dysfunction in a patient comprising administering to the patient an effective dose of a pharmacologic composition; the composition comprising a therapeutic, the therapeutic including a hydrogen sulfide (H2S) donor, or a salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analogs thereof. The H2S donor may be one of sodium sulfide, diallyl trisulfide, diallyl disulfide, allicin, sugammadex, sulfanilamide, disulfiram, sulfonamide, sulfonates, sulfoxides, persulfides, polysulfides, and sulfones. The H2S donor may be sugammadex. The H2S donor may be administered in a dosage of between 0.5 mg/kg and 10.0 mg/kg.

Abstract: A composition and method are disclosed for forming lignin-containing floccules from dissolved lignin, lignin nanoparticles, lignin colloids, or lignin-containing cellulose nanofibers. The floccules may be used to clean oil-contaminated materials such as oil-contaminated plastics or oil-contaminated water. The polymers and oil may then be recovered for further use, without requiring organic solvents.

Abstract: The present invention relates in part to a lignin composition and a method of fabricating a lignin composition. The invention also relates in part to a method of using a lignin composition to adsorb onto a petrochemical oil comprising the steps of providing a solution of lignin in an alcohol, providing an oil on a liquid surface, contacting the oil with the solution of lignin in an alcohol, adsorbing the lignin to the oil, and removing the adsorbed oil from the surface of the liquid.

Abstract: This disclosure provides compounds, pharmaceutical compositions, and methods of use for the prevention and treatment of inflammatory diseases or degenerative diseases including neurodegenerative diseases. Embodiments of the present disclosure provide compounds related to very long chain polyunsaturated fatty acids, pharmaceutical compositions containing the provided compounds, and methods of treating a subject with a condition or disease using provided compounds or pharmaceutical compositions.

Abstract: A respiratory tidal volume monitor and feedback device (RTVMFD) comprising a frame, a flow channel tube attached to the frame, a mass flow sensor disposed on the flow channel tube to detect air flow through the flow channel tube, a microcontroller unit attached to the frame and electrically connected to the mass flow sensor via a bus, the microcontroller unit having a system processor, a system memory, and a system clock, a visual display attached to a top of the frame, the visual display being electrically connected to the bus. According to a further embodiment, the RTVMFD further comprises an audio output attached to the frame and electrically connected to the bus.

Abstract: A method of treating prostate cancer in a patient comprising administering to the patient a pharmaceutical composition including a first therapeutic including a TLK1B inhibitor, or a pharmaceutically acceptable salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analog thereof, and a second therapeutic including an antiandrogen or a pharmaceutically acceptable salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analog thereof.

Abstract: The present invention relates to methods of treating overweight or obesity, reducing fat, sugar, and food intake, and reducing body weight or body weight gain in a subject using geranium oil or orlistat mouthwash, or a combination of both.